Religiosity in patients with Parkinson's disease
Authors Patrick McNamara, Raymon Durso, Ariel Brown
Published Date October 2006 Volume 2006:2(3) Pages 341—348
Published 10 October 2006
Patrick McNamara, Raymon Durso, Ariel Brown
Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA
Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).
Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.
Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.
Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.
Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists
Readers of this article also read:
Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
Srivanichakorn W, Sriwijitkamol A, Kongchoo A, Sriussadaporn S, Plengvidhya N, Lertwattanarak R, Vannasaeng S, Thongtang N
Published Date: 2 March 2015
Letter to the editor regarding "Study design of 'Friends for Life': a process and effect evaluation of an indicated school-based prevention program": response to Lima et al
Kösters MP, Chinapaw MJ, Zwaanswijk M, van der Wal MF, Koot HM
Published Date: 23 April 2014
Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]
Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L
Published Date: 13 June 2013
Qu X, Yao C, Wang J, Li Z, Zhang Z
Published Date: 26 April 2013
Wu Q, Chu M
Published Date: 15 August 2012
Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B
Published Date: 27 July 2012
Published Date: 11 May 2012
Christoforidis J, Ricketts R, Pratt C, Pierce J, Bean S, Wells M, Zhang X, La Perle K
Published Date: 10 January 2012
RA Kurt, K Gündüz
Published Date: 6 September 2010